Mechanisms underlying the role of lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ) in atherosclerotic development are not completely understood. We evaluated the relationship of Lp-PLA 2 with endothelial dysfunction, an early manifestation of atherosclerosis, in a cohort without known clinical cardiovascular disease. A total of 2809 participants in the Multi-Ethnic Study of Atherosclerosis underwent plasma Lp-PLA 2 mass and activity measurement and brachial artery flow-mediated vasodilation testing. In adjusted linear regression models, higher Lp-PLA 2 mass and activity levels were not associated with lower endothelial function (−0.04%, p = 0.51 and −0.09%, p = 0.10, respectively). Among individuals with subclinical atherosclerosis based on ankle-brachial index (ABI) or carotid intima-media thickness (IMT), Lp-PLA 2 mass and activity were not associated with lower endothelial function (−0.03%, p = 0.88 and −0.31%, p = 0.16 for ABI < 1.00; 0.01%, p = 0.94 and −0.15%, p = 0.20 for abnormal carotid IMT). In summary, Lp-PLA 2 is not associated with endothelial dysfunction, suggesting its role in atherosclerosis development is primarily related to other factors.
Introduction
Lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ) hydrolyzes oxidized phospholipids on low-density lipoprotein (LDL) particles, resulting in the formation of proinflammatory and proatherogenic products -lysophosphatidylcholine (LysoPC) and oxidized non-esterified fatty acids (oxFA). 1, 2 These, in turn, play a critical role in the chemotactic response by both stimulating the expression of adhesion molecules and cytokines by endothelial cells and plaque-based macrophages as well as recruiting monocytes and T-lymphocytes. 1, 3, 4 LysoPC has been shown to have adverse effects on endothelial function via increased oxidative stress, modulation of leukocyte chemotaxis, inhibition of endothelial cell migration to sites of endothelial cell damage, and suppression of nitric oxide release. These properties of Lp-PLA 2 have led to its suggested involvement in impaired endothelial function. [5] [6] [7] Elevated Lp-PLA 2 levels are associated with incident cardiovascular events and increased vascular mortality. 8 Data regarding associations of Lp-PLA 2 with endothelial function, however, are limited and have only evaluated epicardial arteries. 9 Impaired flow-mediated dilation is associated with an increased risk of cardiovascular events. 10 Endothelial dysfunction is thought to precede atherosclerotic development and remains impaired in individuals with atherosclerosis assessed by ankle-brachial index (ABI) or carotid intimal-medial thickness (IMT). [11] [12] [13] Considering its specificity for vascular inflammation, determining whether Lp-PLA 2 levels are associated with endothelial dysfunction is important. This knowledge may help to elucidate mechanisms through which this enzyme Association of lipoprotein-associated phospholipase A 2 and endothelial function in the Multi-Ethnic Study of Atherosclerosis (MESA) contributes to atherogenesis. We investigated the association between Lp-PLA 2 levels (mass and activity) and endothelial function in a population with no known cardiovascular disease. We also determined these associations among those with known subclinical atherosclerosis, as defined by an abnormal ABI or carotid IMT.
Methods
Participants came from the Multi-Ethnic Study of Atherosclerosis (MESA) study, a prospective cohort that began in July 2000 to investigate the characteristics associated with subclinical cardiovascular disease and its progression to clinical cardiovascular disease. 14 The population is comprised of 6814 men and women aged 45-84 years with no known cardiovascular disease at baseline. Eligibility requirements were previously described. 14 At study entry, all participants underwent a comprehensive baseline evaluation that included a medical history, physical examination, laboratory investigations, and brachial artery flow-mediated vasodilation (FMD) testing. As part of the MESA FMD study, brachial ultrasound videotapes were evaluated for only a subset (n = 3025) of the cohort for budgetary reasons.
Serum Lp-PLA 2 and circulating adhesion molecule measurement
Both Lp-PLA 2 mass and activity measurements were performed by diaDexus Inc. (South San Francisco, CA, USA). Lp-PLA 2 mass was measured using a sandwich enzyme immunoassay (PLAC™ Test; diaDexus) and Lp-PLA 2 activity was measured by a high-throughput radiometric assay using tritium-labeled platelet activating factor (H 3 -PAF) as the substrate. 15 The interassay coefficients of variation were 6.0% for Lp-PLA 2 mass and 5.0% for Lp-PLA 2 activity.
Biomarkers relating to endothelial function were measured on select, random samples of the cohort and included von Willebrand factor (vWF), soluble intercellular adhesion molecule-1 (ICAM-1), and E-selectin. Amongst participants with their brachial artery FMD analyzed, measurements were available in 726, 2089, and 727 participants, respectively. The characteristics of these subsets did not differ from the overall MESA cohort. The Laboratory for Clinical Biochemistry Research (University of Vermont, Burlington, VT, USA) measured vWF by immunoturbidometric methods on the Sta-R analyzer (Diagnostica Stago, Parsippany, NJ, USA), ICAM-1 by ELISA (R&D Systems, Minneapolis, MN, USA), and E-selectin by sandwich ELISA (R&D Systems).
Brachial artery FMD
Participants were examined in the supine position after 15 minutes of rest and after at least a 6-hour fast. A standard blood pressure cuff was positioned around the right arm, two inches (5.1 cm) below the antecubital fossa, and the artery was imaged 5-9 cm above the antecubital fossa. A linear-array multifrequency transducer operating at 9 MHz was used to acquire images of the right brachial artery. After obtaining baseline images, the cuff was inflated to 50 mmHg above the participant's systolic blood pressure for 5 minutes. Digitized images of the right brachial artery were captured continuously for 30 seconds before cuff inflation and for 2 minutes beginning immediately before cuff deflation to document the vasodilator response.
Images were analyzed at the Wake Forest University Cardiology Image Processing Laboratory with the use of a previously validated semi-automated system to generate the baseline and maximum diameters. 16 These measurements were then used to compute the absolute and percent changes in brachial artery diameter. Intra-reader reproducibility for baseline diameter, maximum diameter and % FMD was evaluated by comparing an original and a blinded quality control re-read of ultrasounds from 40 MESA participants. The intra-class-correlation coefficients were 0.99, 0.99 and 0.93, respectively.
Subclinical atherosclerosis measures
Systolic blood pressure measurements for calculation of the ABI were obtained using a 5-mm Hz probe (Nicolet Vascular, Golden, CO, USA). An abnormal ABI was considered to be a value of 1.00 or less. 17 Participants with an ABI of 1.40 or higher were excluded as it indicates poorly compressible leg arteries and an inability to gauge arterial perfusion accurately. Carotid IMT measurements were performed by an ultrasound reading center at Tufts-New England Medical Center, Boston, Massachusetts and have been previously described. 18 Maximal IMT was defined as the mean maximum IMT value taken from the near and far walls of the right and left sides for both the internal carotid artery (ICA) and common carotid artery (CCA). An abnormal carotid IMT was defined as a value in the highest quintile.
Statistical analysis
Baseline characteristics were compared across quartiles of Lp-PLA 2 mass and activity. General linear models for continuous variables and chi-squared tests for categorical variables were utilized. Pearson correlation coefficients were determined for Lp-PLA 2 mass and activity with each endothelial function biomarker.
Associations with measured brachial FMD for baseline values of Lp-PLA 2 mass and activity were evaluated separately using linear regression analysis, adjusting for age, sex, race/ethnicity, body mass index, diabetes mellitus, smoking status, systolic blood pressure, total and high-density lipoprotein (HDL) cholesterol, medication use (statin, anti-hypertensive), markers of socioeconomic status, and baseline brachial artery diameter (absolute change outcome only). These analyses were performed for each of the following groups: (1) entire cohort, (2) subset with an ABI < 1.00, (3) subset with a carotid IMT in the highest quintile, and (4) subset with both an ABI < 1.00 and a carotid IMT in the highest quintile.
The likelihood of having impaired endothelial function, defined as equal to or more than one standard deviation below the mean, according to standard deviation increments of Lp-PLA 2 levels (mass and activity), were also determined for the above-mentioned groups.
Results
Of 3025 participants with FMD available, 2809 (92.9%) had Lp-PLA 2 mass measured and 2774 (91.7%) had Lp-PLA 2 activity measured. Table 1 shows baseline characteristics for the entire cohort and compares baseline characteristics across quartiles of Lp-PLA 2 activity. Participants with higher Lp-PLA 2 activity were more likely to be male and Caucasian and less likely to be African American or Chinese. Except for a lower prevalence of diabetes across increasing quartiles of Lp-PLA 2 activity, increasing levels of Lp-PLA 2 mass followed similar trends in baseline characteristics. Lp-PLA 2 levels were directly correlated with certain endothelial function biomarkers. Correlation coefficients for Lp-PLA 2 mass with vWF and ICAM-1 were 0.07 (p < 0.05) and 0.16 (p < 0.01), respectively. Correlation coefficients for Lp-PLA 2 activity with E-selectin and ICAM-1 were 0.12 (p < 0.01) and 0.13 (p < 0.01), respectively.
Higher Lp-PLA 2 mass and activity were not significantly associated with lower endothelial function, measured either as a percentage change or absolute change in brachial artery diameter (Table 2) . Looking only at individuals with evidence of subclinical atherosclerosis, there were also no associations between either higher Lp-PLA 2 mass or activity and worse endothelial function (Table 2) . Amongst participants with both a low ABI and carotid IMT in the highest quintile, higher Lp-PLA 2 levels were largely unassociated with impaired endothelial function as well (Table 2 ). In those with a low ABI and an internal carotid IMT in the highest quintile, Lp-PLA 2 activity was associated with a lower percent change (−0.650%, p = 0.04) and absolute change (−0.023 mm, p = 0.04) in FMD, though these findings were only significant in a fully adjusted model.
Neither higher Lp-PLA 2 mass nor activity was associated with the likelihood of impaired endothelial function, defined as an FMD response one standard deviation below the mean, after multivariate adjustment. Prevalence ratios for an impaired percent change in FMD for Lp-PLA 2 mass and activity were 1.01 (95% CI: 0.90-1.14, p = 0.80) and 1.00 (95% CI: 0.91-1.11, p = 0.98), respectively. Prevalence ratios for an impaired absolute change in FMD for Lp-PLA 2 mass and activity were 1.03 (95% CI: 0.93-1.15, p = 0.55) and 1.03 (95% CI: 0.96-1.11, p = 0.43). There remained no significant associations evaluating individuals with either a low ABI or an abnormal carotid IMT.
Discussion
In a population-based sample of individuals with no known clinical cardiovascular disease, Lp-PLA 2 mass and activity were not associated with impaired endothelial function. Lp-PLA 2 levels were also not associated with lower FMD response amongst only those with either a low ABI or an abnormal carotid IMT. Although an association was seen in those with both a low ABI and an abnormal carotid IMT, the sample size was small and findings only became significant in adjusted analyses. These individuals represented a group with relatively advanced subclinical atherosclerosis; associations could be due to chance, unknown confounders or emergence of an association simply due to the presence of subclinical disease. Lp-PLA 2 activity was inversely correlated with the presence of diabetes in this cohort; however, a similar correlation was not found for Lp-PLA 2 mass. Similarly, multiple prior studies have also not reported an inverse correlation between Lp-PLA 2 and diabetes. 19, 20 Exclusion of individuals with diabetes from the primary analysis did not significantly change the findings.
Consistent with prior reports, no correlation existed between Lp-PLA 2 and C-reactive protein (CRP). [21] [22] [23] Lp-PLA 2 and CRP seem to represent two distinct aspects of the inflammatory response. Lp-PLA 2 is considered to be more specific for vascular inflammation whereas CRP is an acute phase reactant and more indicative of generalized inflammation.
Our findings are in contrast to those of Yang et al. who found an association between Lp-PLA 2 levels and coronary endothelial dysfunction in patients with no or mild CAD. 9 Following injection of intracoronary acetylcholine, individuals in the second and third tertiles of Lp-PLA 2 levels had significantly worse changes in coronary blood flow and epicardial coronary artery vasoconstriction. Possible regional differences in the effects of Lp-PLA 2 on endothelial function may account for the discrepant results. Coronary arteries are smaller in caliber than the brachial artery and may respond differently to Lp-PLA 2 . Methodological differences in assessing endothelial function in the coronary and brachial arteries also make it difficult to directly compare results between the two.
To our knowledge, no prior studies have examined the association of Lp-PLA 2 with endothelial dysfunction by brachial FMD. Endothelial cells are key regulators in vascular homeostasis and dysfunction is thought to precede atherosclerotic development. The endothelium promotes vasodilation, inhibits platelet aggregation and adhesion, prevents oxidative modification of LDL cholesterol, limits vascular smooth muscle cell proliferation, and decreases the expression of pro-inflammatory genes that promote atherosclerotic development. In a recent meta-analysis of prospective studies, Lp-PLA 2 mass and activity were associated with a risk of future cardiovascular events and vascular mortality. 1 Whether circulating Lp-PLA 2 levels are a marker of atherosclerosis or reflect plaque activity remains unclear. Lp-PLA 2 has been implicated in various stages of atherosclerotic disease including endothelial dysfunction, plaque inflammation, and necrotic core formation. 2, 24 The correlations of Lp-PLA 2 levels and circulating adhesion molecules in our study, coupled with the lack of a significant association with impaired FMD, suggest that the role of Lp-PLA 2 in atherosclerosis may come after the development of endothelial dysfunction. Although this study is cross-sectional, our results suggest Lp-PLA 2 is not involved in the development of endothelial dysfunction. Future studies of the relationship of Lp-PLA 2 with preclinical forms of atherosclerosis are needed.
